HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. - Wikidata - wikimedia - TriplyDB

HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.

HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.

http://www.wikidata.org/entity/Q36670686

about

Cancer stem cells and signaling pathways in radioresistance The role of peroxiredoxin II in chemoresistance of breast cancer cells Cancer stem cells and radioresistance Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.Nanoparticles for live cell microscopy: A surface-enhanced Raman scattering perspective.HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound.Blocking the formation of radiation-induced breast cancer stem cells.Breast cancer stem cells: Multiple capacities in tumor metastasis.Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells.Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling.Profiling global kinome signatures of the radioresistant MCF-7/C6 breast cancer cells using MRM-based targeted proteomics Genetic and epigenetic analysis of putative breast cancer stem cell models.The role of radiotherapy-resistant stem cells in breast cancer recurrence.HER2 and breast cancer stem cells: more than meets the eye.SIRT3 Enhances Glycolysis and Proliferation in SIRT3-Expressing Gastric Cancer Cells.Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy.Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells.Three-dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer.STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.MKP1 mediates resistance to therapy in HER2-positive breast tumors STAT signaling in different breast cancer sub-types.Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma Characterization of a novel transgenic mouse tumor model for targeting HER2+ cancer stem cells.Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society.The kinome pathways in radioresistance breast cancer stem cells.The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells.HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.Enhanced radiation response in radioresistant MCF-7 cells by targeting peroxiredoxin II.Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Novel methodologies in analysis of small molecule biomarkers and living cells.The network of epithelial-mesenchymal transition: potential new targets for tumor resistance.Adaptive stress signaling in targeted cancer therapy resistance.Metformin and prostate cancer stem cells: a novel therapeutic target.At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology.Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors.Validation of an in vitro model of erbB2(+) cancer cell redirection.

P2860

Q26771576-49903B91-3655-4A01-8F1E-E1916FA25F8A Q26824860-BD51CF2D-F027-4069-88DD-8938BEAB5647 Q27008368-FAA3DD5B-58D6-49E2-9147-A93CAB45047C Q31157425-7C8797F8-7476-416E-93E7-15BF23D34635 Q33718457-3BD6D3C4-36F8-4919-A07A-739318D82643 Q33860870-C0D183D7-FDB3-43B8-A38F-C71F99636740 Q33976964-AA3FE0A8-D8F9-4C5E-B645-D70214569989 Q33977045-C96C84D5-BD6C-4496-A31A-38F08B59F1E3 Q34257303-62E56EE6-6569-4207-8E1D-1CB355C14960 Q34713726-C8D936D9-1BAE-4AF9-82F4-E4EDEC617DBF Q34807238-94099DCC-D5DA-46D3-9EDF-E2E69CF145A5 Q34855520-2737F6D6-EE5A-4542-8116-F060E90C9523 Q34863513-8503D94E-C9F8-4CC3-8573-5CCD83AA6777 Q34972167-BFA61338-9D64-4BBA-B725-078B0A85C18E Q35320325-22359014-1566-4626-84A3-2B1282569FB4 Q35677537-D8F243CA-3A3F-416B-B886-99F9C41D48D7 Q35772708-C13D9142-3342-492B-965C-FC3812E8DF2C Q35977057-00886F1C-14A4-4E77-9C44-3CA550246856 Q36279794-77469F8E-F573-427F-9B1A-DEB72B81B73F Q36516589-5C9CC093-9D0C-4075-9E06-49D0AA9B1235 Q36797292-3C2FFEF7-5E16-4861-A54A-653A8E98B620 Q36916416-F2AC73D9-286E-458F-92EA-EE856C1EDA3E Q36997981-B042C853-8912-4D07-B62A-8468FB4ECF1B Q37086768-4B465203-616C-4F7C-B748-E8A38D87AC0A Q37295655-5C417C66-5295-43B6-B656-D515D9012D78 Q37428738-9957A570-52AC-4E4A-A12C-9D09EB5CB479 Q37470093-78696809-ED7C-4C1E-80D7-55F842645157 Q37528216-B0050E15-251C-4C03-A45D-7A6208239289 Q37562052-2AD8DF9B-32DC-4466-A16F-84DF75AD26F8 Q37564374-91FC1BA3-693A-4F3C-8CCA-64BD3A82CB19 Q37593377-692EA287-40E7-47AE-A840-3D0DA09DAC83 Q37641533-B72BB1C7-B06A-4404-B251-8FB458EFA6B0 Q37650735-8E78BA2B-691E-4D1A-B82E-94E6A377011F Q38239586-0B6EA3F3-8358-4071-9987-8D9159EA392F Q38255668-DFB0BB8E-78AE-4BF6-ADBB-BB8D56F6A39B Q38363739-0D124AA2-53F7-4A9C-9783-18934C6A5598 Q38555403-51BFA639-1C07-4AA9-96F3-A798CCDB5EFB Q38731561-61B325D2-960D-43C7-81D7-C7A1DECA7D0A Q38869428-EBCE3D57-ED59-4392-8F7D-190FA36FB8A9 Q38883916-E9A6AD97-5C98-4D5E-B367-4436084AB6C6

P2860

HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.

http://www.wikidata.org/entity/Q36670686

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

HER2-associated radioresistanc ...... -negative breast cancer cells.

@ast

HER2-associated radioresistanc ...... -negative breast cancer cells.

@en

type

label

HER2-associated radioresistanc ...... -negative breast cancer cells.

@ast

HER2-associated radioresistanc ...... -negative breast cancer cells.

@en

prefLabel

HER2-associated radioresistanc ...... -negative breast cancer cells.

@ast

HER2-associated radioresistanc ...... -negative breast cancer cells.

@en

P1433

Q36670686-274D2C49-F0B9-4202-922E-9A0D41D4F66C

P1476

Q36670686-5AAD3EEC-1894-473C-9EDF-788FDB77699B

P2093

Q36670686-1C90F2AC-F1D7-4919-95D6-8823AEB5EBAD

Q36670686-402D0BA4-9377-4730-A443-A88A3C644613

Q36670686-5D798B55-BB5B-48ED-B410-E69CCB1E1C13

Q36670686-68072D56-CFA2-4008-806D-AB6C978BF9E1

Q36670686-80DD8775-12F8-40FE-B407-C50933C794FC

Q36670686-83FEEFFF-B1ED-485E-9AD9-FD2178B93F8C

Q36670686-884BAE30-242F-469B-A6F8-23D0C0EEF7C2

Q36670686-9406D25E-B17C-4B6F-A606-274EC5D1E615

Q36670686-BC1FB314-0410-4797-BA42-99E9DDCD6869

Q36670686-D6EA73D0-DE7F-4F78-8A07-606DABBE0D20

P2860

Q36670686-02648C2F-55C4-4D8C-95C8-0CA57E346FD8

Q36670686-0A7A2159-C2C9-4B44-B12A-917355EE55E8

Q36670686-0F9CE2F3-B66D-476C-B4B9-2AF041F063F3

Q36670686-14D9D448-58A7-451D-859D-C569B4364881

Q36670686-1FEF5A60-2E98-4D7E-AFFF-DE9CA401AE5A

Q36670686-260710A3-50BB-4DBD-AA66-57CA0551372D

Q36670686-2C3D6E2F-A2C3-4131-86D1-47D6107E4608

Q36670686-2E790631-95DA-46DC-9693-68E0D00997FC

Q36670686-3602DE3A-AFB9-474B-A5A7-A4833DE5CD3F

Q36670686-3A2EF3B0-441C-47C4-BC10-11D681D95C55

P304

Q36670686-EC28A22B-7567-4F1E-941D-260EED7597A5

P31

Q36670686-F2529E04-94BD-4B1F-BB61-303E6452263C

P356

Q36670686-0A3F49AF-33C2-4F51-8B01-CE3F6E2515B4

P407

Q36670686-A6741D9B-B4DC-4319-8C3E-0EA9EE335B0C

P433

Q36670686-77F6CF34-2ED6-4D55-ACCB-884266DD0D3A

P478

Q36670686-C4B3405F-DD8B-49E5-A8D3-A970BEE62E09

P577

Q36670686-098E95AE-755F-4A7B-8A14-3670D119F69D

P698

Q36670686-0827CE88-E822-435E-93C7-C32DFA0628E1

P932

Q36670686-AE5CE4D1-0874-4025-9874-950DFECE2CC7

P356

1078-0432.CCR-12-1436

P1433

Clinical Cancer Research

P1476

HER2-associated radioresistanc ...... -negative breast cancer cells.

@en

P2093

Angela Eldridge

http://www.w3.org/2001/XMLSchema#string

Brett A Chromy

http://www.w3.org/2001/XMLSchema#string

Cheikh Menaa

http://www.w3.org/2001/XMLSchema#string

Danupon Nantajit

http://www.w3.org/2001/XMLSchema#string

Demet Candas

http://www.w3.org/2001/XMLSchema#string

Douglas R Spitz

http://www.w3.org/2001/XMLSchema#string

Hsin-Chen Liu

http://www.w3.org/2001/XMLSchema#string

Jian Jian Li

http://www.w3.org/2001/XMLSchema#string

Kai Xiao

http://www.w3.org/2001/XMLSchema#string

Kit S Lam

http://www.w3.org/2001/XMLSchema#string

P2860

The CD44+/CD24- phenotype is enriched in basal-like breast tumors

Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members

ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Prospective identification of tumorigenic breast cancer cells

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells

Association of reactive oxygen species levels and radioresistance in cancer stem cells

Cancer stem cells: models and concepts

P304

6634-6647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-1436

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23091114

http://www.w3.org/2001/XMLSchema#string

P932

3593096

http://www.w3.org/2001/XMLSchema#string